BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 29247154)

  • 21. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    van der Heijde D; Kivitz A; Schiff MH; Sieper J; Dijkmans BA; Braun J; Dougados M; Reveille JD; Wong RL; Kupper H; Davis JC;
    Arthritis Rheum; 2006 Jul; 54(7):2136-46. PubMed ID: 16802350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 28-Week Results of the GO-ALIVE Trial.
    Reveille JD; Deodhar A; Ince A; Chan EKH; Peterson S; Li N; Hsia EC; Kim L; Lo KH; Xu S; Harrison DD; Han C
    Value Health; 2020 Oct; 23(10):1281-1285. PubMed ID: 33032770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.
    Park W; Yoo DH; Jaworski J; Brzezicki J; Gnylorybov A; Kadinov V; Sariego IG; Abud-Mendoza C; Escalante WJ; Kang SW; Andersone D; Blanco F; Hong SS; Lee SH; Braun J
    Arthritis Res Ther; 2016 Jan; 18():25. PubMed ID: 26795209
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.
    Baeten D; Østergaard M; Wei JC; Sieper J; Järvinen P; Tam LS; Salvarani C; Kim TH; Solinger A; Datsenko Y; Pamulapati C; Visvanathan S; Hall DB; Aslanyan S; Scholl P; Padula SJ
    Ann Rheum Dis; 2018 Sep; 77(9):1295-1302. PubMed ID: 29945918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.
    Inman RD; Davis JC; Heijde Dv; Diekman L; Sieper J; Kim SI; Mack M; Han J; Visvanathan S; Xu Z; Hsu B; Beutler A; Braun J
    Arthritis Rheum; 2008 Nov; 58(11):3402-12. PubMed ID: 18975305
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period.
    Braun J; Deodhar A; Dijkmans B; Geusens P; Sieper J; Williamson P; Xu W; Visvanathan S; Baker D; Goldstein N; van der Heijde D;
    Arthritis Rheum; 2008 Sep; 59(9):1270-8. PubMed ID: 18759257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies.
    Wei JC; Baeten D; Sieper J; Deodhar A; Bhosekar V; Martin R; Porter B
    Int J Rheum Dis; 2017 May; 20(5):589-596. PubMed ID: 28544533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial.
    van der Heijde D; Deodhar A; Braun J; Mack M; Hsu B; Gathany TA; Inman RD; Han C;
    J Rheumatol; 2014 Jun; 41(6):1095-103. PubMed ID: 24737912
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial.
    Huang F; Gu J; Zhu P; Bao C; Xu J; Xu H; Wu H; Wang G; Shi Q; Andhivarothai N; Anderson J; Pangan AL
    Ann Rheum Dis; 2014 Mar; 73(3):587-94. PubMed ID: 23475983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum Vascular Endothelial Growth Factor Levels Lack Predictive Value in Patients with Active Ankylosing Spondylitis Treated with Golimumab.
    Braun J; Baraliakos X; Hermann KG; Xu S; Hsu B
    J Rheumatol; 2016 May; 43(5):901-6. PubMed ID: 26932345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of golimumab on subclinical atherosclerosis and arterial stiffness in ankylosing spondylitis—a randomized, placebo-controlled pilot trial.
    Tam LS; Shang Q; Kun EW; Lee KL; Yip ML; Li M; Li TK; Zhu TY; Pui MO; Li EK; Yu CM
    Rheumatology (Oxford); 2014 Jun; 53(6):1065-74. PubMed ID: 24501241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and Efficacy of Golimumab in Indian Patients with Active Spondyloarthritis of Ankylosing Spondylitis or Psoriatic Arthritis: A Multicenter, Noncomparative, Open-Label, Real-World Study.
    Upadhyaya S; Kumar U; Chandrashekara S; Krishnamurthy V; Bandyopadhyay S; Surin A; Rajasekhar L; Jain N; Nalawade A; Panchal S; Shah N; Korde T; Dixit J
    J Assoc Physicians India; 2024 Mar; 72(3):40-46. PubMed ID: 38736116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
    Li Z; Zhang F; Kay J; Fei K; Han C; Zhuang Y; Wu Z; Hsia EC
    Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kunxian capsules in the treatment of patients with ankylosing spondylitis: a randomized placebo-controlled clinical trial.
    Li Q; Li L; Bi L; Xiao C; Lin Z; Cao S; Liao Z; Gu J
    Trials; 2016 Jul; 17(1):337. PubMed ID: 27449221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study.
    Sieper J; Deodhar A; Marzo-Ortega H; Aelion JA; Blanco R; Jui-Cheng T; Andersson M; Porter B; Richards HB;
    Ann Rheum Dis; 2017 Mar; 76(3):571-592. PubMed ID: 27582421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study.
    Inman RD; Baraliakos X; Hermann KA; Braun J; Deodhar A; van der Heijde D; Xu S; Hsu B
    Arthritis Res Ther; 2016 Dec; 18(1):304. PubMed ID: 28031053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum C-reactive Protein Levels Demonstrate Predictive Value for Radiographic and Magnetic Resonance Imaging Outcomes in Patients with Active Ankylosing Spondylitis Treated with Golimumab.
    Braun J; Baraliakos X; Hermann KG; Xu S; Hsu B
    J Rheumatol; 2016 Sep; 43(9):1704-12. PubMed ID: 27422890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis.
    Inman RD; Maksymowych WP;
    J Rheumatol; 2010 Jun; 37(6):1203-10. PubMed ID: 20231198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radiographic Progression Inhibition with Intravenous Golimumab in Psoriatic Arthritis: Week 24 Results of a Phase III, Randomized, Double-blind, Placebo-controlled Trial.
    Kavanaugh A; Husni ME; Harrison DD; Kim L; Lo KH; Noonan L; Hsia EC
    J Rheumatol; 2019 Jun; 46(6):595-602. PubMed ID: 30770519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Oldfield V; Plosker GL
    BioDrugs; 2009; 23(2):125-35. PubMed ID: 19489653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.